These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35579511)

  • 1. Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603.
    Kawamoto Y; Yuki S; Sawada K; Nakamura M; Muto O; Sogabe S; Shindo Y; Ishiguro A; Sato A; Tsuji Y; Dazai M; Okuda H; Meguro T; Harada K; Sekiguchi M; Okada K; Ito YM; Sakata Y; Sakamoto N; Komatsu Y
    Oncologist; 2022 Aug; 27(8):e642-e649. PubMed ID: 35579511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.
    Xu RH; Zhang Y; Pan H; Feng J; Zhang T; Liu T; Qin Y; Qin S; Yin X; Liu B; Ba Y; Yang N; Voon PJ; Tanasanvimon S; Zhou C; Zhang WL; Shen L
    Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1015-1024. PubMed ID: 34626550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol of OGSG 1901: a phase II trial of ramucirumab plus irinotecan for patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S - 1 therapy.
    Yamaguchi T; Kawakami H; Sakai D; Kurokawa Y; Shimokawa T; Goto M; Satoh T
    BMC Cancer; 2022 Jul; 22(1):773. PubMed ID: 35840917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane.
    Satake H; Sagawa T; Fujikawa K; Hatachi Y; Yasui H; Kotaka M; Kato T; Tsuji A
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):839-845. PubMed ID: 30167847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ramucirumab Beyond Disease Progression After Paclitaxel Plus Ramucirumab in Gastric Cancer: A Phase II Trial.
    Sato Y; Yamashita H; Yagi K; Nomura S; Seto Y
    Anticancer Res; 2024 Jul; 44(7):3125-3131. PubMed ID: 38925825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.
    Yoshikawa T; Muro K; Shitara K; Oh DY; Kang YK; Chung HC; Kudo T; Chin K; Kadowaki S; Hamamoto Y; Hironaka S; Yoshida K; Yen CJ; Omuro Y; Bai LY; Maeda K; Ozeki A; Yoshikawa R; Kitagawa Y
    JAMA Netw Open; 2019 Aug; 2(8):e198243. PubMed ID: 31373648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
    Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
    Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial.
    Song Y; Li N; Li Q; Liang X; Zhang S; Fan Q; Yin X; Zhuang Z; Liu Y; Zhang J; Kou X; Zhong H; Wang X; Dou Y; Huang J
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1b study of ramucirumab in combination with irinotecan plus cisplatin in chemo-naïve patients with extensive-stage small-cell lung cancer.
    Kenmotsu H; Mori K; Mizuno R; Mamesaya N; Kobayashi H; Omori S; Wakuda K; Ono A; Naito T; Murakami H; Takahashi T
    Lung Cancer; 2022 Feb; 164():39-45. PubMed ID: 34974224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
    Bando H; Shimodaira H; Fujitani K; Takashima A; Yamaguchi K; Nakayama N; Takahashi T; Oki E; Azuma M; Nishina T; Hironaka S; Komatsu Y; Shitara K
    Eur J Cancer; 2018 Mar; 91():86-91. PubMed ID: 29353164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Fuchs CS; Shitara K; Di Bartolomeo M; Lonardi S; Al-Batran SE; Van Cutsem E; Ilson DH; Alsina M; Chau I; Lacy J; Ducreux M; Mendez GA; Alavez AM; Takahari D; Mansoor W; Enzinger PC; Gorbounova V; Wainberg ZA; Hegewisch-Becker S; Ferry D; Lin J; Carlesi R; Das M; Shah MA;
    Lancet Oncol; 2019 Mar; 20(3):420-435. PubMed ID: 30718072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
    Tabernero J; Yoshino T; Cohn AL; Obermannova R; Bodoky G; Garcia-Carbonero R; Ciuleanu TE; Portnoy DC; Van Cutsem E; Grothey A; Prausová J; Garcia-Alfonso P; Yamazaki K; Clingan PR; Lonardi S; Kim TW; Simms L; Chang SC; Nasroulah F;
    Lancet Oncol; 2015 May; 16(5):499-508. PubMed ID: 25877855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer.
    Roviello G; Petrioli R; Rosellini P; Multari AG; Conca R; Paganini G; Chiriacò G; Aieta M
    Invest New Drugs; 2019 Jun; 37(3):524-530. PubMed ID: 30687871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.
    Petrylak DP; de Wit R; Chi KN; Drakaki A; Sternberg CN; Nishiyama H; Castellano D; Hussain SA; Fléchon A; Bamias A; Yu EY; van der Heijden MS; Matsubara N; Alekseev B; Necchi A; Géczi L; Ou YC; Coskun HS; Su WP; Bedke J; Gakis G; Percent IJ; Lee JL; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Garcia Del Muro X; Rodriguez-Vida A; Cicin I; Harputluoglu H; Tagawa ST; Vaishampayan U; Aragon-Ching JB; Hamid O; Liepa AM; Wijayawardana S; Russo F; Walgren RA; Zimmermann AH; Hozak RR; Bell-McGuinn KM; Powles T;
    Lancet Oncol; 2020 Jan; 21(1):105-120. PubMed ID: 31753727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.
    Moore M; Gill S; Asmis T; Berry S; Burkes R; Zbuk K; Alcindor T; Jeyakumar A; Chan T; Rao S; Spratlin J; Tang PA; Rothenstein J; Chan E; Bendell J; Kudrik F; Kauh J; Tang S; Gao L; Kambhampati SR; Nasroulah F; Yang L; Ramdas N; Binder P; Strevel E
    Ann Oncol; 2016 Dec; 27(12):2216-2224. PubMed ID: 27733377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer.
    Nakajima TE; Kadowaki S; Minashi K; Nishina T; Yamanaka T; Hayashi Y; Izawa N; Muro K; Hironaka S; Kajiwara T; Kawakami Y
    Clin Cancer Res; 2021 Feb; 27(4):1029-1036. PubMed ID: 33262133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
    Garon EB; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Gorbunova V; Kowalyszyn RD; Pikiel J; Czyzewicz G; Orlov SV; Lewanski CR; Thomas M; Bidoli P; Dakhil S; Gans S; Kim JH; Grigorescu A; Karaseva N; Reck M; Cappuzzo F; Alexandris E; Sashegyi A; Yurasov S; Pérol M
    Lancet; 2014 Aug; 384(9944):665-73. PubMed ID: 24933332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201).
    Kawamoto Y; Yuki S; Meguro T; Hatanaka K; Uebayashi M; Nakamura M; Okuda H; Iwanaga I; Kato T; Nakano S; Sato A; Harada K; Oba K; Sakata Y; Sakamoto N; Komatsu Y
    Oncologist; 2022 May; 27(5):340-e374. PubMed ID: 35303078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer.
    Nakanishi K; Tanaka C; Kanda M; Miyata K; Machida N; Sakai M; Kobayashi D; Teramoto H; Ishiyama A; Sato B; Oshima T; Kajikawa M; Matsushita H; Ishigure K; Yamashita K; Fujitake S; Sueoka S; Asada T; Shimizu D; Sugita S; Kuwatsuka Y; Maeda O; Furune S; Murotani K; Ando Y; Ebata T; Kodera Y
    Nagoya J Med Sci; 2024 Feb; 86(1):43-51. PubMed ID: 38505718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.